Literature DB >> 29467276

Neonatal Jaundice: Improved Quality and Cost Savings After Implementation of a Standard Pathway.

Holly M Romero1,2,3, Coral Ringer3, Michael G Leu2,3,4, Elaine Beardsley3, Karen Kelly3, Megan D Fesinmeyer5, Wren L Haaland5, James B Johnson3, Darren Migita2,3.   

Abstract

OBJECTIVES: Seattle Children's Hospital sought to optimize the value equation for neonatal jaundice patients by creating a standard care pathway.
METHODS: An evidence-based pathway for management of neonatal jaundice was created. This included multidisciplinary team assembly, comprehensive literature review, creation of a treatment algorithm and computer order sets, formulation of goals and metrics, roll-out of an education program for end users, and ongoing pathway improvement. The pathway was implemented on May 31, 2012. Quality metrics before and after implementation were compared. External data were used to analyze cost impacts.
RESULTS: Significant improvements were achieved across multiple quality dimensions. Time to recovery decreased: mean length of stay was 1.30 days for 117 prepathway patients compared with 0.87 days for 69 postpathway patients (P < .001). Efficiency was enhanced: mean time to phototherapy initiation was 101.26 minutes for 14 prepathway patients compared with 54.67 minutes for 67 postpathway patients (P = .03). Care was less invasive: intravenous fluid orders were reduced from 80% to 44% (P < .001). Inpatient use was reduced: 66% of prepathway patients were admitted from the emergency department to inpatient care, compared with 50% of postpathway patients (P = .01). There was no increase in the readmission rate. These achievements translated to statistically significant cost reductions in total charges, as well as in the following categories: intravenous fluids, laboratory, room cost, and emergency department charges.
CONCLUSIONS: An evidence-based standard care pathway for neonatal jaundice can significantly improve multiple dimensions of value, including reductions in cost and length of stay.
Copyright © 2018 by the American Academy of Pediatrics.

Entities:  

Mesh:

Year:  2018        PMID: 29467276     DOI: 10.1542/peds.2016-1472

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  6 in total

1.  Exploration of the pathogenic factors of neonatal jaundice and the clinical effect of blue phototherapy.

Authors:  Bixin Yu; Fangqi Hu
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

2.  Effect of humanized care in the treatment of neonatal jaundice and its effect on oxygen saturation.

Authors:  Chunmei Yan; Leilei Zhou; Xiaolin Kang
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

3.  Prevalence and burden of illness of treated hemolytic neonatal hyperbilirubinemia in a privately insured population in the United States.

Authors:  Tzy-Chyi Yu; Chi Nguyen; Nancy Ruiz; Siting Zhou; Xian Zhang; Elaine A Böing; Hiangkiat Tan
Journal:  BMC Pediatr       Date:  2019-02-11       Impact factor: 2.125

Review 4.  The Effects of Clofibrate on Neonatal Jaundice: A Systematic Review.

Authors:  Fathemeh Eghbalian; Ali Hasanpour-Dehkordi; Roya Raeisi
Journal:  Int J Prev Med       Date:  2022-01-19

5.  Deimplementation of Polycythemia Screening in Asymptomatic Infants in a Level 1 Nursery.

Authors:  Scarlett C Johnson; Elizabeth Bigus; Patricia L Thompson; David G Bundy; Michelle I Amaya
Journal:  Pediatr Qual Saf       Date:  2022-03-30

6.  Implementation of Febrile Infant Management Guidelines Reduces Hospitalization.

Authors:  Lauren Z Foster; Joshua Beiner; Carol Duh-Leong; Kira Mascho; Victoria Giordani; Michael L Rinke; Leonardo Trasande; Ethan Wiener; Rebecca E Rosenberg
Journal:  Pediatr Qual Saf       Date:  2020-01-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.